Clopidogrel Monotherapy After PCI in Patients with High Bleeding Risk

Overview

About this study

The primary aims of this study are to test the hypothesis that clopidogrel monotherapy is safe following successful PCI among 100 consecutive patients with HBR and meeting the inclusion criteria, and to determine the incidence of BARC 3 or 5 bleeding events among participants enrolled in Aims 1 and 2.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Informed consent in adults

- Successful percutaneous coronary intervention (PCI) [no non-fatal MI/stroke/repeat
target revascularization/bleeding/acute kidney injury].

- Academic research consortium-high bleeding risk (ARC-HBR) score ≥ 4.

Exclusion Criteria:

- Chronic use of warfarin or direct oral anticoagulant (DOAC).

- Unsuccessful PCI (see above).

- Lesions with angiographic thrombus.

- Prior PCI within 6 months.

- Planned PCI or surgical intervention to treat any cardiac or noncardiac condition
within 6 months.

- High risk lesion/stent characteristics (> 50% unprotected left main disease,
bifurcation disease requiring 2 stents technique, rotational atherectomy.

- Vein graft.

- Unprotected left main intervention or history of definite stent thrombosis.

- Women of child-bearing age unless negative pregnancy test is done.

- Life expectancy < 1 year.

- Known drug/alcohol dependence.

- Assessment that the patient will not be compliant with the study protocol.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Mandeep Singh, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Mandeep Singh, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials